Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Rhea-AI Summary
Avalo Therapeutics (NASDAQ: AVTX) priced an underwritten public offering to raise approximately $375 million in gross proceeds by selling 19,730,000 shares of common stock and pre-funded warrants to purchase 1,400,000 shares.
The offering price is $17.75 per share and $17.749 per pre-funded warrant; the underwriters have a 30-day option for up to 3,169,500 additional shares. Closing is expected May 7, 2026, subject to customary conditions. Net proceeds will fund Phase 3 development of abdakibart and general corporate purposes.
AI-generated analysis. Not financial advice.
Positive
- Gross proceeds of approximately $375 million
- 19.73M common shares and 1.4M pre-funded warrants offered
- Proceeds earmarked to advance abdakibart Phase 3 and topline data
- Underwriters granted a 30-day option for up to 3,169,500 additional shares
Negative
- Issuance will cause shareholder dilution to existing holders
- Gross proceeds are before underwriting discounts, commissions and expenses
- Closing is subject to customary conditions and may not occur on May 7, 2026
News Market Reaction – AVTX
On the day this news was published, AVTX gained 34.13%, reflecting a significant positive market reaction. Argus tracked a peak move of +91.0% during that session. Argus tracked a trough of -34.0% from its starting point during tracking. Our momentum scanner triggered 99 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $111M to the company's valuation, bringing the market cap to $434.91M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AVTX is up 18% while the momentum scanner shows no peers in active momentum. Listed peers show mixed single‑digit moves (e.g., AGEN +2.71%, ZURA ‑3.36%), pointing to a stock‑specific reaction rather than a sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Milestone buyout deal | Positive | -10.8% | Replaced a $15M contingent Phase 3 milestone with smaller structured payments. |
| Mar 23 | Earnings and update | Neutral | +0.6% | Reported 2025 results with $98.3M cash and higher R&D-driven net loss. |
| Feb 24 | Investor conferences | Neutral | +9.5% | Announced March 2026 healthcare conference presentations and webcast availability. |
| Feb 18 | Inducement grants | Neutral | +6.5% | Granted options for 82,000 shares at $14.26 to new employees. |
| Feb 04 | Investor conferences | Neutral | -10.0% | Outlined February 2026 conference fireside chats and webcast access. |
Recent AVTX news has often produced sizable but mixed price reactions, with several events showing moves that diverge from the apparent tone of the announcements. Conference participation and routine corporate updates have triggered both double‑digit gains and losses, suggesting a trading environment highly sensitive to positioning and expectations rather than just headline direction.
Over the last few months, Avalo has reported financial results, conference participation, equity inducement grants and a milestone buyout tied to its AlmataBio acquisition. Notable items include $98.3M in year‑end 2025 cash, a $78.3M net loss for 2025, and restructuring of a $15M Phase 3 milestone into smaller near‑term payments and an option. These steps framed expectations around funding and development needs, into which today’s sizeable public equity offering fits as an added capital source.
Regulatory & Risk Context
Avalo has an effective Form S-3 shelf dated Jan 8, 2026 allowing offerings of up to $750,000,000 in various securities, plus $326,585,963 carried forward from an expiring shelf under Rule 415(a)(6). The current underwritten public offering, documented via a 424B5 filed on May 5, 2026, represents at least one usage of this shelf to raise equity capital.
Market Pulse Summary
The stock surged +34.1% in the session following this news. A strong positive reaction aligns with AVTX’s history of sharp moves after major updates, even on complex news. The company already had an effective S-3 shelf for up to $750,000,000, and this $375M offering taps that capacity. While added capital may support advancing abdakibart into registrational studies, investors have previously seen price swings that diverged from seemingly neutral events, suggesting sensitivity to positioning and deal terms.
Key Terms
underwritten public offering financial
pre-funded warrants financial
exercise price financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
rule 10b5-1 trading plan regulatory
form 144 regulatory
AI-generated analysis. Not financial advice.
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of
Avalo intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to advance the clinical development of abdakibart, including through its Phase 3 topline data release, and for working capital and other general corporate purposes.
Leerink Partners, TD Cowen, BofA Securities, Piper Sandler and Cantor are acting as joint bookrunning managers for the offering.
The securities described above are being offered pursuant to shelf registration statement on Form S-3 (No. 333-292614) that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 8, 2026, and was declared effective on January 20, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.
The preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on May 5, 2026. A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and BofA Securities, Attention: Prospectus Department, 201 North Tryon Street, NC1-022-02-25 Charlotte, NC 28255- 0001, or by email at dg.prospectus_requests@bofa.com; Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; and Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York 10022 or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, and include, but are not limited to, statements regarding the expected gross proceeds from the offering, completion and timing of the public offering and the anticipated use of proceeds from the offering. Any forward-looking statements are based on Avalo’s current expectations, forecasts, and assumptions and are subject to a number of risks and uncertainties that could cause actual outcomes and results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Avalo’s actual results to differ from those contained in the forward-looking statements in this press release, see the section entitled “Risk Factors” in Avalo’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic filings with the SEC, as well as in the prospectus supplement related to the public offering. Forward-looking statements contained in this press release are based on information available to Avalo as of the date hereof and are made only as of the date of this release. Avalo undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Avalo’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Avalo.
Investor & Media Contact:
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
Or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
